Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

By Georgina V. Long, V. Atkinson, S. Lo, S. Sandhu, A. Guminski, M. Brown, J. Wilmott, J. Edwards, Maria Gonzalez, R. Scolyer and 2 more. The Lancet Oncology, 2018

835 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a3a116678cfbd747eae37b5a52a404540da4edf1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Joyce
2. R. Weinberg

Citations in the corpus

• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “patients [II, A] [66], or elevated lactate dehydrogenase (LDH) with a PFS/OS HR of”
• Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells (2020, background): “However, although they show some clinical efficacy in a subset of BrM patients (Hendriks et al., 2019; Long et al., 2018; Tawbi et al., 2018), ICB has only resulted in responses in isolated cases of primary gliomas to date (Lim et al.”